Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

ClinicalTrials.gov ID: NCT03336619

Public ClinicalTrials.gov record NCT03336619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.

Study identification

NCT ID
NCT03336619
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Romark Laboratories L.C.
Industry
Enrollment
1,030 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 16, 2018
Primary completion
Apr 16, 2019
Completion
Apr 16, 2019
Last update posted
Jun 27, 2022

2018 – 2019

United States locations

U.S. sites
34
U.S. states
16
U.S. cities
31
Facility City State ZIP Site status
Vanguard Study Site Alabaster Alabama 35007
Vanguard Study Site Birmingham Alabama 35235
Vanguard Study Site Birmingham Alabama 35242
Vanguard Study Site Hoover Alabama 35216
Vanguard Study Site Pelham Alabama 35124
Vanguard Study Site Goodyear Arizona 85338
Vanguard Study Site Tolleson Arizona 85353
Vanguard Study Site Hot Springs Arkansas 71913
Vanguard Study Site Anaheim California 92805
Vanguard Study Site Westminster California 92683
Vanguard Study Site Lauderdale Lakes Florida 33319
Vanguard Study Site Orlando Florida 32806
Vanguard Study Site Valparaiso Indiana 46383
Vanguard Study Site New Orleans Louisiana 70124
Vanguard Study Site St Louis Missouri 63141
Vanguard Study Site Missoula Montana 59808
Vanguard Study Site Brooklyn New York 11229
Vanguard Study Site Cincinnati Ohio 45215
Vanguard Study Site Columbus Ohio 43214
Vanguard Study Site Dayton Ohio 45424
Vanguard Study Site Medford Oregon 97504
Vanguard Study Site Rapid City South Dakota 57702
Vanguard Study Site Jackson Tennessee 38305
Vanguard Study Site Smyrna Tennessee 37167
Vanguard Study Site Austin Texas 78735
Vanguard Study Site Carrollton Texas 75010
Vanguard Study Site Dallas Texas 75204
Vanguard Study Site Dallas Texas 75230
Vanguard Study Site Fort Worth Texas 76107
Vanguard Study Site Houston Texas 77058
Vanguard Study Site Pharr Texas 78577
Vanguard Study Site Plano Texas 75024
Vanguard Study Site Plano Texas 75093
Vanguard Study Site St. George Utah 84790

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03336619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2022 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03336619 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →